Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EONS13: Evolving roles in cancer nursing

CN27 - Value of nurse navigators (NNs) telemonitoring for cancer patients (pts) tested positive for COVID-19

Date

19 Sep 2020

Session

EONS13: Evolving roles in cancer nursing

Topics

COVID-19 and Cancer

Tumour Site

Presenters

Delphine Mathivon

Citation

Annals of Oncology (2020) 31 (suppl_4): S1076-S1078. 10.1016/annonc/annonc317

Authors

D. Mathivon1, M. Abbas1, A. Barrais1, A. Duflot-Boukobza1, M. Ferrua2, J. Legendre1, C. Mendes1, M. Merad2, E. Minvielle2, O. Mir1, M. Pons1, F. Scotté1

Author affiliations

  • 1 Care Pathways, Gustave Roussy, 94805 - Villejuif/FR
  • 2 Research Department, Gustave Roussy, 94805 - Villejuif/FR

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract CN27

Background

The current COVID-19 pandemic has raised a major challenge to healthcare systems. Deployment of telehealth solutions can help maintaining continuity of care while limiting pts' and healthcare workers’ exposure with the virus. In this context, Gustave Roussy Cancer Institute has implemented a pts reported outcome platform (CAPRI-COVID) to improve monitoring and effective management of COVID-19 positive pts with cancer.

Methods

CAPRI-COVID consists in a mobile application (CAPRI App) and a telephone platform with a dedicated call number, the entire procedure being managed by four NNs. After an initial assessment by the NNs, remote monitoring of 6 COVID-related symptoms were collected daily, either by the patient via the CAPRI App or by NNs during a phone call. In case of worsening or emerging symptoms, an automated alert was sent to the platform; NN assessed the clinical condition and could ask for a medical advice if necessary. The monitoring period was 14 days (with at least 2 days with complete regression of symptoms). Each intervention performed by NNs was tracked on the platform, as well as pts-reported data. This analysis presents the data collected via the platform from March 23 to May 4 2020.

Results

Overall, 116 COVID-positive pts have completed the monitoring period (median age: 58.5 years, 21-90; 56.9% female). 54.3% were monitored after hospitalization for COVID-19, 37.1% after RT-PCR screening (symptomatic pts) and 8.6% for systematic screening prior to surgery. There were no deaths or admissions to intensive care unit. 7.8% of pts were hospitalized (excluding scheduled hospitalization). NNs conducted an average of 9.9 calls per patient. Of 53 events requiring a medical opinion, 50.9% resulted in a visit to the emergency room. 41.4% of pts downloaded the CAPRI App, and completed the tracking data on average 1.1 times per day.

Conclusions

CAPRI-COVID enabled to keep the majority of pts at home, and helped to ensure secure pts’ pathways during this epidemic. NNs play an essential role in addition with the use of CAPRI App which helped limiting phone calls and focusing on the management of complex pts. Ongoing analyses are exploring actions of NNs and pts’ experience.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Gustave Roussy.

Funding

Has not received any funding.

Disclosure

O. Mir: Honoraria (self), Travel/Accommodation/Expenses: Amgen; Honoraria (self), Honoraria (institution): AstraZeneca ; Honoraria (self), Research grant/Funding (institution): Bayer; Honoraria (institution), Advisory/Consultancy, Research grant/Funding (institution): Blueprint Medicines ; Honoraria (self): Bristol-Myers Squibb ; Honoraria (self), Speaker Bureau/Expert testimony, Research grant/Funding (institution): Eli Lilly ; Honoraria (self), Honoraria (institution), Advisory/Consultancy, Shareholder/Stockholder/Stock options: Ipsen; Honoraria (self): Lundbeck ; Honoraria (self): MSD; Honoraria (self), Honoraria (institution): Novartis; Honoraria (self), Honoraria (institution), Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Pfizer ; Honoraria (self), Honoraria (institution), Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Roche; Honoraria (self), Speaker Bureau/Expert testimony: Servier; Honoraria (self): Vifor Pharma ; Shareholder/Stockholder/Stock options: Amplitude Surgical ; Honoraria (self), Shareholder/Stockholder/Stock options: Transgene ; Honoraria (institution): PharmaMar. F. Scotté: Honoraria (self): CIO Roche; Honoraria (self): MSD; Honoraria (self): Pierre fabre Oncology; Honoraria (self): Leo Pharma; Honoraria (self): BMS; Honoraria (self): Pfizer; Honoraria (self): Mundi Pharma; Honoraria (self): Mylan. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.